Form4insider filings, from the source

SEC Form 4 · accession 0000899243-19-002662

Global Blood Therapeutics, Inc. · GBT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jeffrey S Farrow
Officer — Chief Financial Officer
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Feb 1, 2019M5,938—A21,493D
Common StockF2Feb 1, 2019F2,164$48.44D19,329D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F3$48.44Feb 1, 2019A40,000A—Jan 31, 2029Common Stock40,00040,000D
Restricted Stock UnitsF1,F4—Feb 1, 2019A25,000A——Common Stock25,00025,000D
Restricted Stock UnitsF1,F5—Feb 1, 2019M3,063D——Common Stock3,06312,250D
Restricted Stock UnitsF1,F6—Feb 1, 2019M2,875D——Common Stock2,87517,250D

Explanation of responses